Protocol for Microbiome Transplantation in Suckling Mice during *Vibrio cholerae* Infection to Study Commensal-Pathogen Interactions

The gut microbiome plays an important role in the exclusion of pathogens and, thus, infection outcomes. Microbiome-pathogen interaction studies are complicated by a lack of tractable animal models and differences in animal model versus human microbiomes. We have adapted the suckling mouse model of infection of the human pathogen *Vibrio cholerae* to clear murine microbes and establish human-associated gut microbes during infection. Our method allows for the easy examination of the contribution of different human microbial communities to enteropathogenesis.

**HIGHLIGHTS**

- A protocol for testing interactions of human microbiomes and *Vibrio cholerae*
- Depletion of murine commensals allows for replacement with human gut bacteria
- Detailed procedures for preparation of bacterial mixtures and gavage of suckling mice
Protocol for Microbiome Transplantation in Suckling Mice during *Vibrio cholerae* Infection to Study Commensal-Pathogen Interactions

Salma Alavi¹,²,⁎ and Ansel Hsiao¹,³,⁎

¹Department of Microbiology and Plant Pathology, University of California, Riverside, Riverside, CA 92521, USA
²Technical Contact
³Lead Contact
⁎Correspondence: salav002@ucr.edu (S.A.), ansel.hsiao@ucr.edu (A.H.)

https://doi.org/10.1016/j.xpro.2020.100200

SUMMARY

The gut microbiome plays an important role in the exclusion of pathogens and, thus, infection outcomes. Microbiome-pathogen interaction studies are complicated by a lack of tractable animal models and differences in animal model versus human microbiomes. We have adapted the suckling mouse model of infection of the human pathogen *Vibrio cholerae* to clear murine microbes and establish human-associated gut microbes during infection. Our method allows for the easy examination of the contribution of different human microbial communities to enteropathogenesis.

For complete details on the use and execution of this protocol, please refer to Alavi et al. (2020).

BEFORE YOU BEGIN

The gut microbiome participates in numerous host-related phenotypes, including susceptibility to pathogens. The substantial differences between human and native animal model microbiomes complicate studies of microbiome-pathogen interactions (Seedorf et al., 2014). Conventionally-reared animals without modification are highly refractory to *V. cholerae* colonization (Olivier et al., 2009), while existing germ-free animal models for cholera are expensive and difficult to breed and maintain. Here, we describe an easily accessible animal model for studying interactions between human gut microbiome and *V. cholerae* in the context of infection. We have adapted the popular suckling mouse model of *V. cholerae* infection (Klose, 2000) through pre-infection treatment with the antibiotic streptomycin to substantially reduce existing mouse microbes, followed by the establishment of human-associated gut microbes to examine microbiome-pathogen interactions during infection. Animals can be inoculated with complex human fecal specimens or with defined mixtures of pure bacterial cultures.

**Option 1: Prepare Defined Communities of Bacteria for Gavage**

© Timing: 1–2 h, ~72 h incubation, 30 min next 3 days, ~48 h incubation, 1–2 h next 2 days

**Note:** Systems for generating anaerobic conditions may vary. We performed experiments using a Coy vinyl anaerobic chamber with internal incubator cabinet and atmosphere of 7% H₂, 20% CO₂, and balance N₂. The chamber employs a palladium catalyst reacting with H₂ to remove atmospheric oxygen by conversion to water. Typical O₂ concentrations are <10 ppm.
1. Ensure that there is sufficient deoxygenated media for experiment available. At least 3 days before the start of the experiment, place sterilized reagents, and autoclaved glass vials and crimp-top sealing caps with polyurethane septa, into anaerobic chamber with loose caps to allow for deoxygenation/pre-reduction.

2. Prepare media and reagents. Refer to “Materials and Equipment” for component list of LYH-BHI media. Add all components except hemin to a glass beaker. Stir at 52°C and add hemin until dissolved. When the solution is clear, sterilize by filtration through 0.22 μm filter. Filter-sterilize 50% vol/vol glycerol and place into anaerobic chamber.

3. Prepare glycerol stocks from pure culture of anaerobic human isolates. Streak to single colony of suitable agar growth medium and pick one isolated colony for inoculation into 5 mL liquid broth. For anaerobic strains, culture at 37°C in anaerobic chamber until late logarithmic phase (varies by species). Mix 1:1 vol/vol culture with filter-sterilized and deoxygenated 50% glycerol, mix by pipetting, and aliquot 300 μL in 2 mL glass vials with crimp-top caps with polyurethane septa. Place crimp-seal caps on vials with forceps sterilized with 70% vol/vol ethanol and crimp to seal. Cycle from anaerobic chamber and freeze immediately at −80°C.

4. To start cultures for colonization, thaw the glycerol stock cultures of the bacterial strains in anaerobic chamber at room temperature (20°C–22°C). Stocks of aerobic strains can be thawed outside the chamber. Remove culture by syringe from thawed glycerol stock into 5 mL LYH-BHI media. Incubate for 3 days at 37°C.

△ CRITICAL: If the strain is a strict anaerobe, incubate and prepare cultures and stocks under anaerobic conditions.

Note: Culture preparation for colonization studies starts 5 days before the start of the experiment. Preparation of complex human fecal samples can start on the same day of the start of the experiment.

5. After 3 days (2 days before the start of the experiment), dilute the cultures (1:50) in fresh LYH-BHI media. Incubate at 30°C for 48 h.

6. After 2 days (on the day of the experiment), measure the optical density (OD₆₀₀) of the culture. Use at least 100 μL of the culture for measurement.

7. Normalize cultures for density by OD₆₀₀. The equivalent of a total of 300 μL of 0.4 OD₆₀₀ culture should be divided evenly across strains by community. For example, a gavage of a 10-member defined community will contain the equivalent number of cells in 30 μL of 0.4 OD₆₀₀ culture of each member strain.

8. Mix the calculated amount for each strain together, centrifuge for 2 min at 9,000 × g to pellet. Resuspend combined cell pellet in fresh LYH-BHI media to a maximum of 50 μL per suckling mouse.

△ CRITICAL: Pelleting of anaerobic strains should be performed in an anaerobic chamber. For mixed anaerobic/aerobic strains, pellet aerobic strains in normal atmosphere, and transfer cell pellets to the anaerobic chamber to resuspend in fresh deoxygenated LYH-BHI media.

Note: Amount of LYH-BHI to resuspend cell pellets varies based on number of animals to be gavaged. Each mouse receives a maximum gavage volume of 50 μL. Mice not receiving *V. cholerae* at time of gavage can receive a community mixture of 50 μL. For co-infections, the cells of the community mixture should be resuspended in 25 μL final volume, with the remaining 25 μL being the *V. cholerae* inoculum, generally 1 × 10⁶–1 × 10⁸ CFU *V. cholerae* in LB media.

Note: More than one gavage may be required if the first is not successful. In this case, gavages can be attempted while the mouse is still slowed from first exposure to isoflurane. If the mouse...
does not appear well or the color of the skin has changed, place back in the incubator and try to gavage again after 15–30 min.

9. Prepare *Vibrio cholerae* inoculum. One day before the start of colonization experiment, inoculate *V. cholerae* from glycerol stock in 3 mL LB media and incubate at 37°C for 18 h. On the day of the experiment dilute the culture (1:100 vol/vol) in fresh LB in 125 mL flask and incubate at 37°C for 3 h with 250 rpm agitation on shaking incubator until the OD

900 reaches ~ 0.3. Dilute culture (1:10) in fresh LB. Pellet by centrifugation, and transfer cell pellet into anaerobic chamber and resuspend in 1 mL deoxygenated LYH-BHI. Dilute 1:1,000 of this for gavage. Each mouse receives 25 μL of *Vibrio cholerae* inoculum.

△ CRITICAL: When preparing gavages for a large number of mice, some of the inoculum will remain in the needle and syringe. To ensure that sufficient inoculum is available, consider preparing 2 times more inoculum than calculated as necessary for the number of mice to be gavaged.

### Option 2: Prepare Complex Human Fecal Samples for Gavage

© Timing: 4–5 h (after sample collection), 1–2 h on the day of the experiment

10. Human fecal samples are collected separately from each donor in specimen collection containers of choice (e.g., Fisherbrand Commode Specimen Collection System). After collection, stool samples can be processed immediately or frozen at –80°C (for up to 6 months) for later processing.

**Note:** Pooled samples would not be appropriate for the determination of inter-individual variation in pathogen-microbiome interactions.

11. To begin sample processing, transfer fecal specimens into anaerobic chamber on ice. Remove 2–3 cm piece with chisel sterilized with 70% vol/vol ethanol and weigh. Add 1:3 weight/volume of sterile deoxygenated PBS containing 0.1% wt/vol cysteine. Vortex for 5 min to resuspend.

12. After resuspending in PBS, pass sample through the sterile 70 μm cell strainer to remove large particulates.

13. Add sterile deoxygenated 50% weight/volume sterile glycerol to a final concentration of 25% vol/vol glycerol. Aliquot into 500 μL into 2 mL glass vial (large opening crimp-top). Sterilize tips of tweezers with 70% vol/vol ethanol and use to place 11 mm crimp-seal red rubber septa (cap). Take care to avoid contact with the interior of the cap. Crimp cap to seal. Freeze stocks immediately at –80°C.

14. Quantify the bacteria in each sample by quantitative real-time PCR measurement of bacteria 16S DNA. Normalize fecal slurries to be representative of 16S levels in 300 μL of OD

900=0.4 culture of defined community described above. Primers: 5’-CTCCTACGGGAGGCAGCAG-3’, 5’-TTACCGCGGCTGCTGAC-3’.

**Note:** For detailed protocol of quantitative real-time PCR, please refer to (Alavi et al., 2020).

15. On the day of the experiment, thaw sufficient prepared stocks in anaerobic chamber (volume requirements depend on number of animals; see step 7, Before You Begin for calculation). Centrifuge the calculated amount for 2 min at 9,000 x g to pellet. Resuspend cell pellet in fresh LYH-BHI media. LYH-BHI volume depends on the number of mice to be gavaged. See above after step 8.

16. If you have any aerobic strains, prepare as explained above, take the pellet to the anaerobic chamber and resuspend in calculated amount of fresh LYH-BHI or suitable media.
## KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Bacterial and Virus Strains** | | |
| *Vibrio cholerae* C6706 El Tor | Hsiao Lab stock | C6706 |
| **Biological Samples** | | |
| Human volunteer donor fecal sample | Alavi et al., 2020 | N/A |
| **Chemicals, Peptides, and Recombinant Proteins** | | |
| Isoflurane liquid inhalation 99.9% glass bottle 250 mL | Henry Schein | N/A |
| BHI broth (granulated) | Research Products International | Cat# B11000-1000.0 |
| Yeast extract | Thermo Fischer Scientific | Cat# 210929 |
| Hemin | MP Biomedicals | Cat# ICN19882010 |
| Cellobiose | Fischer Scientific | Cat# AC108461000 |
| Maltose | Millipore Sigma | Cat# M5885 |
| Cysteine | Millipore Sigma | Cat# C6852 |
| NaCl | Fischer Scientific | Cat# S271-10 |
| Tryptone | Fischer Scientific | Cat# BP1421-500 |
| Agar, powdered, Bacto-Style | Genesee Scientific | Cat# 20-274 |
| PBS 10X powder concentrate | Fisher Bioreagents | Cat# BP665-1 |
| Phenol:chloroform:isoamyl alcohol (25:24:1) | Fisher Scientific | Cat# BP1752400 |
| SDS | Fisher Scientific | Cat# O2674-25 |
| Isopropanol | Fisher Scientific | Cat# A4644 |
| Sodium acetate | Millipore Sigma | Cat# S8750 |
| Glycerol | Genesee | Cat# 18-205 |
| Ethanol | Decon Labs | Cat# V1016 |
| Streptomycin | Fisher Bioreagents | Cat# BP910-50 |
| **Experimental Models: Organisms/Strains** | | |
| Mouse: CD1 IGS | Charles River Laboratories | N/A |
| Mouse: C57/BL6 | UCR gnotobiotic facility | N/A |
| **Other** | | |
| Coy vinyl anaerobic chamber system | Coy Lab Products | N/A |
| Vial, large opening crimp-top 2.0 mL | Chemglass Lifesciences | Cat# 50230754 |
| Crimp-seal, 11 mm/red rubber septa | Chemglass Lifesciences | Cat# 50-153-2572 |
| 125 mL flask | Fisher Scientific | Cat# S63270 |
| Commode Specimen Collection System | Fisher Scientific | Cat# 02-544-208 |
| Intramedic PE Tubing .111NID 1 × 100 ft | BD | Cat# 1417012P |
| PrecisionGlide single-use needles 30 g | BD | Cat# 1482113A |
| 1 mL syringe | BD | Cat# BD-309628 |
| 500 m: wide-mouth polypropylene jar with lid | Fisher Scientific | Cat# 02-891E |
| 50 mL polypropylene beaker | Fisher Scientific | Cat# 1205-0050 |
| General-purpose pinning forceps (4.5 inch) | Fisher Scientific | Cat# 10270 |
| Dissecting scissors | Fisher Scientific | Cat# 08-951-10 |
| 2mL sterile microcentrifuge tubes with screw caps | Fisher Scientific | Cat# 2681374 |

(Continued on next page)
Continued

**REAGENT or RESOURCE** | **SOURCE** | **IDENTIFIER**
--- | --- | ---
Tissue homogenizer | Biospec | Cat# 985370
0.1 mm zirconia/silica beads | Biospec | Cat# NC0362415
Incubator (gravity convection) | Fisher Scientific | Cat# 51028112
Sterile cell strainer 70 µm | Fisher Scientific | Cat# 22-363-548
0.22 µm 500 mL Steritop filter | Millipore | Cat# SCGVT05RE
Fisherbrand Commode Specimen Collection System | Fisher Scientific | Cat# 02544208

**Oligonucleotides**
Forward Primer: 5'-CTCCTACGGGAGGCAGCAG-3' | Alavi et al., 2020 | N/A
Reverse Primer: 5'-TTACCGCGGCTGCTGGCAC-3' | Alavi et al., 2020 | N/A

**MATERIALS AND EQUIPMENT**

| Reagent | Concentration | Amount (for 1 L) |
| --- | --- | --- |
| **LYH-BHI media** |  | |
| BHI broth (granulated) | 37 g/L | 37 g |
| Yeast extract | 5 g/L | 5 g |
| Hemin | 5 mg/L | 5 mg |
| Cellobiose | 1 g/L | 1 g |
| Maltose | 1 g/L | 1 g |
| Cysteine | 0.5 g/L | 0.5 g |
| ddH₂O | – | to 1 L |
| **LB media** |  | |
| NaCl | 5 g/L | 5 g |
| Tryptone | 10 g/L | 10 g |
| Yeast Extract | 5 g/L | 5 g |
| ddH₂O | – | to 1 L |
| Bacto-agar (for plates) | 15 g/L | 15 g |

**Note:** LYH-BHI media can be stored under anaerobic conditions at room temperature (20°C–22°C) for up to 3 months in opaque or foil-wrapped containers. LB can be stored at room temperature (20°C–22°C) for up to 6 months.

**STEP-BY-STEP METHOD DETAILS**

**Preparation of Suckling Mice for Gavage**

○ **Timing:** 1 h on day 0

△ **CRITICAL:** Specific-pathogen free (SPF) mice need to be pre-treated with oral antibiotics for 24 h prior to introduction of bacteria. Gavage procedures for antibiotics and bacteria cultures or human fecal specimens are identical.
Note: All 30°C steps are in incubator with open water pan to maintain humidity.

1. Mice should be 4 days old at time of antibiotic administration. CD-1 suckling animals were purchased from Charles River Laboratories. Germ-free suckling animals were obtained from the UCR gnotobiotic animal facility. Similar results have been obtained with C57/BL6 background suckling animals, and specific mouse backgrounds may be more appropriate depending on the pathogen of interest.

2. Fast infants (separate them from the lactating dam) for 1.5 h before gavage. Place pups in 50 mL plastic beaker lined with paper-towel or Kimwipe in 30°C incubator with open water pan to maintain humidity.

3. During fasting period, prepare materials needed for gavage including isoflurane, 30-gauge plastic tubing, glycerol, 30G x 1 needles, and 1 mL syringe.

4. Target antibiotic dosing is 1 mg/g body weight streptomycin. Based on the average weight of 4 days old suckling mice, concentration of streptomycin in 50 µL gavage would be 75 mg/mL in ddH2O. Gavage procedure for streptomycin is identical to that described in steps 6–12.

Preparation of Bacterial Gavage

*Timing: 2 h on each day 1 and day 2*

5. Place the 50 mL beaker containing fasted animals in 500 mL plastic jar (wide-mouth polypropylene jar with lid) lined with tissue paper or Kimwipe (Figure 1A).

6. Take a representative animal, place the plastic tubing to be used for gavage parallel to their body, and mark on the tube using permanent marker the distance from the tubing end represented by the snout to the stomach measurement (Figure 1B). During gavage, tubing will need to be inserted until this mark reaches the snout of the animal to ensure intra-gastric inoculation (Figure 2).

7. Absorb 150 µL of isoflurane into tissue paper in jar.

    △ CRITICAL: This prevents direct exposure of skin to isoflurane, which can cause pain/discomfort.

    △ CRITICAL: Work inside chemical fume hood when working with isoflurane.

8. Place suckling mouse to be inoculated in small interior container (Figure 1C), re-place the lid on the outer container, and wait 30 s (Figure 1D).

    **Note:** For anaesthetization of 2 mice, use ~300 µL isoflurane.

    △ CRITICAL: Be careful not to tighten the lid of the outer container.

9. Take the bacterial mixtures (either complex or cultured microbiomes with *V. cholerae*, see steps 8 or 15, and step 9 in Before you Begin) that have already been prepared by syringe from the vial. Place the tubing on the needle using forceps sterilized with 70% vol/vol ethanol (see Methods Video S1), and dip the marked area of the tubing in sterile 50% glycerol to lubricate tubing.

10. Carefully insert tubing into the mouth of the suckling mouse, aligning the trajectory of the tubing to match the esophagus (Figure 2).

11. Once the mark on tubing reaches the snout, inject 50 µL of the inoculum into stomach. For example of complete gavage procedure, see Methods Video S2.

12. After each gavage, place mouse back in 30°C incubator.

13. After 15 min to disperse any residual isoflurane, place infants with dam.
14. The next day, after preparing the cultures for gavage, fast the suckling mice in 30°C for 1.5 h.
15. Repeat the gavage with bacteria cultures/human fecal samples.
16. Place inoculated mice separated from dam in 30°C incubator for 15–16 h.

**Mouse Dissection and Intestinal Homogenization**

**Timing:** 4–5 h

17. Anesthetize the mice using the two-container method as described above for gavage, but add 1 mL isoflurane and close the outer lid tightly.
18. After 4–5 min, remove mice from container. Perform cervical dislocation to euthanize, and prepare for dissection.

△ CRITICAL: Disinfect all the forceps and scissors by ethanol (let them dry by air).

19. Spray 70% vol/vol ethanol on the surface of the body and allow it to air dry.
20. Make initial incision in the abdominal wall with dissection scissors (Figure 3). Continue excision laterally, taking care not to cut the intestine. Gently cut fascia binding the intestines so that they can be removed intact.
21. Once the intestines are moved out of the body cavity, cut at the proximal end where duodenum joins the stomach and at the distal end of the ileum.
22. Place the small intestine on the clean dissection tray. Divide the small intestine to three equal sections by length (Figure 4). For example of complete dissection procedure, see Methods Video S3.

23. Place each section in 5 mL sterile PBS.
24. Use tissue homogenizer to fully break the tissue.
   a. Initially pulse the homogenizer in sterile water for 30 s.
   b. Move to 100% vol/vol ethanol, and repeat.
   c. Pulse in third container of sterile water, and then homogenize tissue at full power for 60 s.

   **Note:** Repeat these steps (a, b, and c) after each homogenization.

25. To extract DNA from the homogenate sample.
a. Transfer 500 µL of homogenate to 2 mL screw-cap tube with ~500 µL 0.1 mm zirconia/silica beads (autoclaved).
b. Add 210 µL 20% wt/vol SDS.
c. Add 500 µL phenol:chloroform:isoamyl alcohol (25:24:1).
d. Bead beat on high speed for 2 min to disrupt tissue and lyse cells.
e. Centrifuge 16,000 × g at 4°C for 15 min.
f. Remove aqueous phase into new tube.
g. Add 500 µL phenol:chloroform:isoamyl alcohol, mix by inversion for 15 s.
h. Centrifuge 16,000 × g at 4°C for 15 min.
i. Remove aqueous phase into new tube.
j. Add 600 µL of −20°C isopropanol, 60 µL (1/10 volume) 3 M sodium acetate and mix by inversion.
k. Place in −20°C for 16 h or −80°C for 1 h.
l. Centrifuge at 16,000 × g for 30 min at 4°C.
m. Decant supernatant.

26. For CFU enumeration of *V. cholerae* in homogenate:
a. Add 10 µL of intestinal homogenate to 90 µL sterile PBS.
b. Serially dilute 10-fold until 10⁻⁴ dilution.
c. Plate 50 µL of the 10⁻³ and 10⁻⁴ dilution on the LB agar containing 200 mg/mL streptomycin.
d. Incubate plates at 30°C 16–18 h and count colonies to determine colonization level of *V. cholerae* (see Figure 5).

**EXPECTED OUTCOMES**

In this antibiotic-cleared mice model, the mice microbiome is ablated, allowing for the establishment of added human-associated bacteria in the mouse gut. The level of depletion can be quantified by extraction of DNA from intestinal homogenates followed by quantitative real-time PCR for microbial 16S genes using universal primers (Alavi et al., 2020). For a gavage of 1 × 10⁴–1 × 10⁵ CFU of *V. cholerae*, a colonization level of 10⁶–10⁸ CFU / small intestine is expected after overnight infection depending on the defined community used. The level of colonization for mice also receiving complex human fecal specimens range from 1.5 × 10⁶–4 × 10⁷ CFU.

**LIMITATIONS**

The method described here is only suitable for short term colonization experiments, as suckling mice cannot survive without long-term access to lactating dam. Replacing colonized pups with dam
introduces differences in available nutrients and thus potentially different microbiome configurations, as diet is a potent driver of microbiome structure (Charbonneau et al., 2016). Non-dietary milk components are also able to directly interact with V. cholerae during infection in mice, potentially confounding microbiome-dependent results (Hsiao et al., 2006). Long-term colonization also risks cannibalization of sick pups before microbial data can be obtained. Previous studies involving continuous colonization with pups also have required substantially larger and more frequent administrations of V. cholerae to maintain colonization (Mao et al., 2018).

At the indicated doses of V. cholerae, the majority of microbes recovered after overnight infection are pathogens. For examination of microbiome-specific transcriptional or metabolomic activity during infection in vivo, the dosing of V. cholerae will need to be reduced. We also recommend the inclusion of uninfected control groups to examine in vivo commensal activity and viability. Intestinal samples from such animals can be used for 16S rRNA amplicon sequencing to determine the similarity of the transplanted community to the original fecal specimen.

The microbiomes endemic to individual animal facilities and backgrounds may differ, along with the presence of potentially streptomycin-resistant commensal organisms. Different antibiotic regimens may be required to ablate the murine microbiome prior to transplantation of human fecal specimens.

For the preparation of defined communities containing microbes requiring specific growth conditions, LYH-BHI may not be appropriate.

**TROUBLESHOOTING**

**Problem 1**
High levels of variability in colonization per mouse or failed colonization (step 11, Step-by-Step).

**Potential Solution**
Pups can regurgitate the gavage. To determine if the gavage is retained, add ~1 μL of food dye (filter-sterilized) to the gavage preparation. The inoculum will then be just visible in the stomach of pups under the skin.
Problem 2
Cannibalization of pups by dam after colonization (step 16, Step-by-Step).

Potential Solution
After gavage, make certain to disperse residual isoflurane before putting pups back with the dam. This can be accomplished by maintaining them for at least 15–20 min in incubator after gavage to make sure.

Problem 3
Mouse injury can happen during the gavage. Mouse deaths can happen from improper gavage (step 11, Step-by-Step).

Potential Solution
Suckling mice should be checked frequently in the hour after gavage to ensure that they are moving. Attrition due to gavage can lead to the loss of some animals, which should be accounted for in the number of animals available at the start of the experiment.

RESOURCE AVAILABILITY
Lead Contact
Further information and requests for resources should be directed to and will be fulfilled by the Lead Contact, Ansel Hsiao (ansel.hsiao@ucr.edu).

Materials Availability
Source of commercial mouse lines are indicated in Key Resources Table. Unique microbial strains and samples are available from the Lead Contact with a completed Materials Transfer Agreement.

Data and Code Availability
This study did not generate or analyze datasets/code.

SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.xpro.2020.100200.

ACKNOWLEDGMENTS
This work was supported by National Institute of General Medical Sciences grant R35GM124724 (to A.H.).

AUTHOR CONTRIBUTIONS
All authors designed and analyzed experiments. S.A. performed experiments. S.A. and A.H. wrote the paper.

DECLARATION OF INTERESTS
The authors declare no competing interests.

REFERENCES
Alavi, S., Mitchell, J.D., Cho, J.Y., Liu, R., Macbeth, J.C., and Hsiao, A. (2020). Interpersonal gut microbiome variation drives susceptibility and resistance to cholera infection. Cell 181, 1533–1546.e3.

Charbonneau, M.R., O’Donnell, D., Blanton, L.V., Totten, S.M., Davis, J.C., Barratt, M.J., Cheng, J., Guruge, J., Talcott, M., Bain, J.R., et al. (2016). Sialylated milk oligosaccharides promote microbiota-dependent growth in models of infant undernutrition. Cell 164, 859–871.

Hsiao, A., Liu, Z., Joelsson, A., and Zhu, J. (2006). Vibrio cholerae virulence regulator-coordinated evasion of host immunity. Proc. Natl. Acad. Sci. U S A 103, 14542–14547.

Klose, K.E. (2000). The suckling mouse model of cholera. Trends Microbiol. 8, 189–191.

Mao, N., Cubillos-Rua, A., Cameron, D.E., and Collins, J.J. (2018). Probiotic strains detect and suppress cholera in mice. Sci. Transl. Med. 10, eaao2586.

Olivier, V., Queen, J., and Satchell, K.J. (2009). Successful small intestine colonization of adult mice by Vibrio cholerae requires ketamine anesthesia and accessory toxins. PLoS One 4, e7352.

Seedorf, H., Queen, J., and Satchell, K.J. (2009). Successful small intestine colonization of adult mice by Vibrio cholerae requires ketamine anesthesia and accessory toxins. PLoS One 4, e7352.

Seedorf, H., Griffin, N.W., Ridaura, V.K., Reyes, A., Cheng, J., Rey, F.E., Smith, M.I., Simon, G.M., Schellfruh, R.H., Woebken, D., et al. (2014). Bacteria from diverse habitats colonize and compete in the mouse gut. Cell 159, 253–266.